Patents by Inventor Andrea Rizzi

Andrea Rizzi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRROLIDINE DERIVATIVES AS DDRS INHIBITORS
    Publication number: 20240425482
    Abstract: The present invention relates to compounds of formula (I) inhibiting Discoidin Domain Receptors (DDR inhibitors), methods of preparing such compounds, intermediate compounds useful in such preparations, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful for instance in the treatment of many disorders associated with DDR mechanisms.
    Type: Application
    Filed: October 17, 2022
    Publication date: December 26, 2024
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Laura CARZANIGA, Fabio RANCATI, Andrea RIZZI, Eleonora GHIDINI, Nicolò IOTTI, Roberta MAZZUCATO, Stefano LEVANTO, Ben Paul WHITTAKER
  • TETRAHYDROTHIENO PYRIDINE DERIVATIVES AS DDRS INHIBITORS
    Publication number: 20240391936
    Abstract: The present invention relates to compounds of general formula (I) inhibiting Discoidin Domain Receptors (DDR inhibitors), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful for instance in the treatment of many disorders associated with DDR mechanisms.
    Type: Application
    Filed: March 25, 2022
    Publication date: November 28, 2024
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Laura CARZANIGA, Andrea RIZZI, Nicoió IOTTI, Fabio RANCATI, Anna KARAWAJCZYK, Barbara Karolina WOLEK, David Edward CLARK, Toby Matthew Grover MULLINS, Keith Christopher KNIGHT, Ben Paul WHITTAKER, Stefano LEVANTO
  • HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS
    Publication number: 20240279240
    Abstract: The present invention relates to a compounds of general formula (I) inhibiting the JAK family of non-receptor tyrosine protein kinases (JAK1, JAK2, JAK3, and TYK2), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of the JAK family non-receptor kinases; in particular for the treatment of various inflammatory disease including asthma, COPD and other respiratory diseases.
    Type: Application
    Filed: March 14, 2022
    Publication date: August 22, 2024
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Alessandro ACCETTA, Fabio RANCATI, Andrea RIZZI, Alberto CUZZOLIN, Milan MESIC, Rahela ZADRAVEC, Dinko ZIHER, Ivaylo ELENKOV
  • INDOLINE DERIVATIVES AS DDRS INHIBITORS
    Publication number: 20240217967
    Abstract: The present invention relates to compounds of general formula (I) inhibiting Discoidin Domain Receptors (DDR inhibitors), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful for instance in the treatment of many disorders associated with DDR mechanisms.
    Type: Application
    Filed: March 25, 2022
    Publication date: July 4, 2024
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Laura CARZANIGA, Fabio RANCATI, Andrea RIZZI, Nicolò IOTTI, Keith Christopher KNIGHT, Toby Matthew Grover MULLINS, Anna KARAWAJCZYK, Ben Paul WHITTAKER
  • HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS
    Publication number: 20240209001
    Abstract: The present invention relates to a compounds of general formula (I) inhibiting the JAK family of non-receptor tyrosine protein kinases (JAK1, JAK2, JAK3, and TYK2); methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of the JAK family non-receptor kinases; in particular for the treatment of various inflammatory disease including asthma, COPD and other respiratory diseases.
    Type: Application
    Filed: March 14, 2022
    Publication date: June 27, 2024
    Applicant: CHIESI FARMACEUTICI S.P. A.
    Inventors: Alessandro ACCETTA, Fabio RANCATI, Andrea RIZZI, Alberto CUZZOLIN, Milan MESIC, Dinko ZIHER, Ivaylo ELENKOV, Kristina BUTKOVIC
  • TETRAHYDROTHIENO PYRIDINE DERIVATIVES AS DDRS INHIBITORS
    Publication number: 20240199635
    Abstract: The present invention relates to compounds of general formula (I) inhibiting Discoidin Domain Receptors (DDR inhibitors), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful for instance in the treatment of many disorders associated with DDR mechanisms.
    Type: Application
    Filed: March 25, 2022
    Publication date: June 20, 2024
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Laura CARZANIGA, Fabio RANCATI, Andrea RIZZi, Keith Christopher KNIGHT, Anna KARAWAJCZYK, Barbara Karolina WOLEK, Toby Matthew Grover MULLINS, Ben Paul WHITTAKER
  • INDOLINE DERIVATIVES AS DDR1 AND DDR2 INHIBITORS
    Publication number: 20240190847
    Abstract: The present invention relates to compounds of general formula (I) inhibiting DDR1 and DDR2. Particularly, the invention relates to compounds that are indoline derivatives, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of DDRs, in particular fibrosis.
    Type: Application
    Filed: March 25, 2022
    Publication date: June 13, 2024
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Laura CARZANIGA, Fabio RANCATI, Andrea RIZZI, Anna KARAWAJCZYK, Barbara Karolina WOLEK, Toby Matthew Grover MULLINS
  • HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS
    Publication number: 20240166651
    Abstract: The present invention relates to a compounds of general formula (I) inhibiting the JAK family of non-receptor tyrosine protein kinases (JAK1, JAK2, JAK3, and TYK2); methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of the JAK family non-receptor kinases; in particular for the treatment of various inflammatory disease including asthma, COPD and other respiratory diseases.
    Type: Application
    Filed: March 14, 2022
    Publication date: May 23, 2024
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Alessandro ACCETTA, Fabio RANCATI, Andrea RIZZI, Dinko ZIHER, Milan MESIC, Ivaylo ELENKOV
  • AMIDO CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS
    Publication number: 20230250093
    Abstract: The present invention relates to compounds of general formula (I) inhibiting lysophosphatidic acid receptor 1 (LPA1), particularly the invention relates to compounds that are Ami do cyclohexane acid derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of LPA receptors, in particular fibrosis.
    Type: Application
    Filed: July 15, 2021
    Publication date: August 10, 2023
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Elisabetta ARMANI, Gabriele AMARI, Andrea RIZZI, Mafalda PAGANO, Luca RAVEGLIA, Claudia BEATO
  • BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS
    Publication number: 20230227447
    Abstract: The present invention relates to a compounds of general formula (I) inhibiting DDR1 and DDR2, particularly the invention relates to compounds that are benzylamine derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of DDRs, in particular fibrosis.
    Type: Application
    Filed: May 24, 2021
    Publication date: July 20, 2023
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Laura CARZANIGA, Fabio RANCATI, Andrea RIZZI, Anna KARAWAJCZYK, Bartosz Pawel GUT
  • Isoxazolidine derivatives
    Patent number: 10280193
    Abstract: Anti-inflammatory and antiallergic compounds of the glucocorticosteroid series, according to formula (I) according to formula (I) defined herein are useful for treating diseases of the respiratory tract characterized by airway obstruction.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: May 7, 2019
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Eleonora Ghidini, Andrea Rizzi
  • Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
    Patent number: 10196386
    Abstract: Compounds of formula I defined herein act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive or inflammatory diseases.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: February 5, 2019
    Assignee: CHIESI FARMACEUTICI S.P.A.
    Inventors: Fabio Rancati, Andrea Rizzi, Laura Carzaniga, Ian Linney, Chris Knight, Wolfgang Schmidt
  • 3,5-dichloro,4-(3,4-(cyclo-)alkoxyphenyl)--2-carbonyloxy)ethyl)pyridine derivatives as PDE-4 inhibitors
    Patent number: 10087176
    Abstract: The invention relates to novel 3,5-dichloro,4-(3,4-(cyclo-) alkoxyphenyl)-2-carbonyloxy)ethyl)pyridine compounds which are inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists, methods of preparing such compounds, compositions containing them and therapeutic use thereof.
    Type: Grant
    Filed: June 4, 2014
    Date of Patent: October 2, 2018
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Gabriele Amari, Elisabetta Armani, Mauro Riccaboni, Andrea Rizzi, Charles Baker-Glenn, Wesley Blackaby, Herve Van De Poel, Ben Whittaker
  • Compounds having muscarinic receptor antagonist and BETA2 adrenergic receptor agonist activity
    Patent number: 10004728
    Abstract: Compounds of formula I, defined herein, act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for treating broncho-obstructive and inflammatory diseases.
    Type: Grant
    Filed: January 12, 2017
    Date of Patent: June 26, 2018
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Fabio Rancati, Andrea Rizzi, Laura Carzaniga, Ian Linney, Chris Knight, Wolfgang Schmidt
  • Compounds having muscarinic receptor antagonist and BETA2 adrenergic receptor agonist activity
    Patent number: 9932338
    Abstract: Compounds of formula (I), defined herein, act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive or inflammatory diseases.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: April 3, 2018
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Laura Carzaniga, Fabio Rancati, Andrea Rizzi, Ian Linney
  • ISOXAZOLIDINE DERIVATIVES
    Publication number: 20180066010
    Abstract: Anti-inflammatory and antiallergic compounds of the glucocorticosteroid series, according to formula (I) according to formula (I) defined herein are useful for treating diseases of the respiratory tract characterized by airway obstruction.
    Type: Application
    Filed: November 8, 2017
    Publication date: March 8, 2018
    Applicant: CHIESI FARMACEUTICI S.p.A.
    Inventors: Eleonora GHIDINI, Andrea Rizzi
  • COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY
    Publication number: 20180016267
    Abstract: Compounds of formula I defined herein act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive or inflammatory diseases.
    Type: Application
    Filed: July 12, 2017
    Publication date: January 18, 2018
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Fabio RANCATI, Andrea Rizzi, Laura Carzaniga, Ian Linney, Chris Knight, Wolfgang Schmidt
  • Isoxazolidine derivatives
    Patent number: 9845337
    Abstract: Anti-inflammatory and antiallergic compounds of the glucocorticosteroid series, according to formula (I) according to formula (I) defined herein are useful for treating diseases of the respiratory tract characterized by airway obstruction.
    Type: Grant
    Filed: November 10, 2014
    Date of Patent: December 19, 2017
    Assignee: CHIESI FARMACEUTICI S.P.A.
    Inventors: Eleonora Ghidini, Andrea Rizzi
  • COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY
    Publication number: 20170158694
    Abstract: Compounds of formula (I), defined herein, act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive or inflammatory diseases.
    Type: Application
    Filed: November 30, 2016
    Publication date: June 8, 2017
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Laura CARZANIGA, Fabio RANCATI, Andrea RIZZI, Ian LINNEY
  • 3,5-DICHLORO,4-(3,4-(CYCLO-)ALKOXYPHENYL)--2-CARBONYLOXY)ETHYL)PYRIDINE DERIVATIVES AS PDE-4 INHIBITORS
    Publication number: 20170152256
    Abstract: The invention relates to novel 3,5-dichloro,4-(3,4-(cyclo-) alkoxyphenyl)-2-carbonyloxy)ethyl)pyridine compounds which are inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists, methods of preparing such compounds, compositions containing them and therapeutic use thereof.
    Type: Application
    Filed: June 4, 2014
    Publication date: June 1, 2017
    Applicant: Chiesi Farmaceutici S.p.A.
    Inventors: Gabriele AMARI, Elisabetta ARMANI, Mauro RICCABONI, Andrea RIZZI, Charles BAKER-GLENN, Wesley BLACKABY, Herve VAN DE POEL, Ben WHITTAKER